Scientific exchange · Dr. Ximena Rossi

02 Sept 2026 · In person · Dr. Ximena Rossi, Osaka University Hospital · MSL Mei Tanaka · Vantrexa

ReviewedVeeva CRMENG-0092—

Capture insight from this engagement

Location: Osaka University Hospital
Therapeutic area: Oncology
Country: Japan
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: MTMei TanakaMSL, Oncology (Japan)
Product: Vantrexa (vantrelimab)

Topics discussed

Infusion-reaction management
Duration of response
Chemotherapy-free first line

Scientific content used

VOYAGE-1 pivotal data summary
VTX core scientific deck v3.2

Questions raised

What is the evidence for re-challenge with checkpoint inhibitors after progression on vantrelimab?
How should grade 2 infusion reactions be managed without steroids?

Notes

Scientific exchange with radiation oncologist at Osaka University Hospital. Discussed infusion-reaction management, duration of response, chemotherapy-free first line.

Insights captured (1)

Capture insight

INS-0066Medium
Infusion-reaction management
Infusion-reaction management: practice variation observed reported by radiation oncologist (JP).
Submitted

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 3
Depth of exchange: 2
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0092

Audit history (0)

All create, update and approval events for this record

No audit events in sample data